Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

47.91
-2.3200-4.62%
Post-market: 47.84-0.0700-0.15%18:43 EDT
Volume:7.17M
Turnover:345.96M
Market Cap:5.90B
PE:12.75
High:50.25
Open:50.25
Low:47.50
Close:50.23
Loading ...

Halozyme Therapeutics Q4 2024 Adj EPS $1.26 Beats $1.16 Estimate, Sales $298.00M Beat $288.24M Estimate

Benzinga
·
19 Feb

Halozyme Therapeutics Reiterates FY 2025 Guidance For EPS of $4.95-$5.35 on Revenue of $1.15-$1.225 Billion, vs FactSet Analyst Consensus of $4.90/Share on Revenue of $1.19 Billion

MT Newswires Live
·
19 Feb

Halozyme Therapeutics Inc - Reiterating 2025 Financial Guidance

THOMSON REUTERS
·
19 Feb

BRIEF-Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million

Reuters
·
19 Feb

Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million

THOMSON REUTERS
·
19 Feb

Halozyme Therapeutics Q4 Operating Income USD 175.501 Million

THOMSON REUTERS
·
19 Feb

Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD

TIPRANKS
·
18 Feb

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

GlobeNewswire
·
18 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
18 Feb

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Zacks
·
17 Feb

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

Zacks
·
14 Feb

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Zacks
·
13 Feb

Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

Halozyme Therapeutics Says Non-Small Cell Lung Cancer Treatment Gets Positive Opinion in Europe

MT Newswires Live
·
03 Feb

Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics

TIPRANKS
·
03 Feb

Halozyme announces positive opinion in EU for rybrevant with Enhanze technology

TIPRANKS
·
03 Feb

Chmp Issues Positive Opinion for Subcutaneous Rybrevant®(Amivantamab) Co-Formulated With Enhanze® for the Treatment of Patients With Advanced Egfr-Mutated Non-Small Cell Lung Cancer

THOMSON REUTERS
·
03 Feb

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Zacks
·
31 Jan

High Growth Tech Stocks To Watch In January 2025

Simply Wall St.
·
31 Jan

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Zacks
·
27 Jan